Kutatási jelek – Signal Engine

• A neoantigen vaccine generates antitumour immunity in renal cell carcinoma — Renal cell carcinoma
• Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements — Ovarian cancer
• Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer — Ovarian cancer
• Gastroesophageal Cancer Treatment: Practice Advances — SCLC
• Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence — Prostate cancer
• Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions — NSCLC
• Breast cancer: pathogenesis and treatments — Breast cancer
• Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies — Breast cancer
• Immunotherapy improves endometrial cancer outcomes — Endometrial cancer
• Selpercatinib for RET-Positive Lung, Medullary Thyroid Cancers — NSCLC
• Treatment of Acute Myeloid Leukaemia — Acute myeloid leukemia
• Thyroidectomy without Radioiodine in Patients with Low‑Risk Thyroid Cancer — Thyroid cancer
• FDA Clears IND for TERN-701 for Chronic Myeloid Leukemia — Chronic myeloid leukemia
• Advances in Endometrial Cancer Research — Endometrial cancer
• Understanding the Treatment of Waldenström's Macroglobulinemia — Diffuse large B-cell lymphoma
• A dual institution real-world study of avelumab for advanced Merkel cell carcinoma — Merkel cell carcinoma
• Early clinical trial highlights cancer vaccines as potential affordable, safe and effective breast cancer treatment — Breast cancer
• Testing Shorter Chemo‑Immunotherapy Without Anthracycline Drugs for Early‑Stage Triple Negative Breast Cancer — Breast cancer
• CGT9486+Sunitinib vs Sunitinib in People with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) — Gastrointestinal stromal tumor
• ASCO 2023 Breast Cancer Clinical Trial Updates — Breast cancer